ABT 546

Drug Profile

ABT 546

Alternative Names: A 216546; ABT-546

Latest Information Update: 12 Feb 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abbott Laboratories
  • Class
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cardiovascular disorders

Most Recent Events

  • 31 Dec 2012 Discontinued - Phase-I for Cardiovascular disorders in USA (unspecified route) before 2012
  • 06 Mar 2003 No development reported - Phase-I for Cardiovascular disorders in USA (unspecified route)
  • 06 Jun 2001 Phase-I clinical trials for Cardiovascular disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top